ProMIS™ Neurosciences, Inc.

ProMIS Neurosciences' CEO, Neil Warma, recently sat down with CEOCFO Magazine to discuss his new role as CEO. In this interview, he talks about the concept behind ProMIS, the unique science and technology that we use to target and clear toxic misfolded proteins that cause neurodegenerative diseases, and the potential impact that our drug candidates can have on the lives of millions of patients suffering from multiple dementias, such as Alzheimer’s, Parkinson’s, and ALS.   Check out the full interview here! https://lnkd.in/eHTxQTzb   #AlzheimersDisease #ALS #Neurodegeneration #DrugDevelopment #Collaboration #PMN #ParkisonsDisease #ALS #Biotech

This week, ProMIS is participating in the Sequire Investor Summit to showcase the Company’s exciting pipeline in neurodegenerative diseases and highlight its value proposition. View the program here: https://lnkd.in/gVKZMcYv   #SRAX24 #PMN #NeurodegenerativeDiseases #AlzheimersDisease 

The ProMIS Neurosciences Board and team are excited to welcome Neil Warma as the new Chief Executive Officer (Interim). Neil’s leadership and neuroscience background ideally positions him to advance our ongoing clinical program and foster partnerships that will drive innovation in dementias and other neurodegenerative disease treatments. Neil has worked globally in the US, Europe and Asia and has deep expertise in drug development and commercialization. He also brings a strong business development background to the Company, having negotiated several deals with large pharmaceutical companies. We are all looking forward to an exciting 2024. Read the full press release: https://lnkd.in/eeVxjDXS   #neurodegenerativediseases #Alzheimers #ALS #CEO #PMN

ProMIS is delighted to have dosed the first subjects in our first-in-humans Phase 1a clinical trial of PMN310 to treat Alzheimer’s disease (AD). We believe our selective targeting of toxic Aβ oligomers, which avoids monomer distraction and plaque binding, will potentially provide differentiation from the first generation of Abeta-directed antibodies. To learn more, see our press release at: https://lnkd.in/dKT3kk3R #ClinicaTrials #AlzheimersDisease #Neurodegeneration #DrugDiscovery #AβOligomers #PMN #FirstInHumanStudies

ProMIS CEO, Gail Farfel, Ph.D., will be speaking at the CNS Summit to discuss the various ways we can be collaborating to bring novel solutions to the development of new medicines to treat neurodegenerative disease. With a spotlight on neuroscience, Dr. Farfel will be sharing ProMIS’ novel antibody therapeutics approach that targets toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease. We expect this to be an exciting CNS Summit as growing evidence shows that scientific collaboration plays a crucial role in transformative innovation in the life sciences.    #CNSSummit #NeuroscienceSpotlight #NeurodegerativeDisease #DrugDevelopment #AlzheimersDisease #Collaboration #PMN

ProMIS Neurosciences is proud to have Johanne Kaplan, Ph.D., the Company’s Chief Development Officer, participate in the Canadian Initiative for Translational Neuroscience’s Industry Roundtable, where she will discuss Improving Public-Private Partnerships to Advance Drug Discovery with a panel of industry, academic and foundation leaders.     Worldwide life expectancy is rising, yet longer life expectancy is linked to an increased risk of neurodegenerative disorders. Now more than ever, it is imperative we find innovative ways to collaborate on the development of new therapies to battle these debilitating diseases.   #AlzheimersDisease #ALS #Neurodegeneration #DrugDevelopment #Collaboration #PMN

ProMIS Neurosciences commemorates World Alzheimer’s Day and supports the Alzheimer’s Disease International’s goal to raise awareness of this debilitating disease for the estimated 6.7 million Americans living with Alzheimer’s dementia. At ProMIS, we are advancing PMN310, a next-generation, potential best-in-class anti-amyloid therapy that is highly selective for only misfolded, toxic oligomers, does not bind monomer and does not bind plaque or vascular deposits. We are looking forward to dosing our first-in-humans study of PMN310 in the near-term and believe PMN310 has significant potential to be a best-in-class therapy for Alzheimer’s disease. Importantly, we are also developing a vaccine capable of inducing an effective antibody response against pathogenic Aβ, which could be administered as a preventative measure to at-risk individuals to prevent the development of symptomatic disease or which could be given therapeutically to diagnosed patients to inhibit the progression of Alzheimer’s disease. With development candidates to both prevent and treat Alzheimers’s disease, ProMIS is clearly aligned with this year’s World Alzheimer’s Day theme, “Never too early; Never too Late.” #WorldAlzheimersDay #AlzheimersDisease #CNSDiseases #Drug Development #Neurodegeneration 

ProMIS Neurosciences is very pleased to join the #Alzheimers community in celebrating the FDA's full approval of LEQEMBI® for Alzheimer’s disease. We congratulate our industry colleagues at Eisai, Biogen, and the patients and families on their success. At ProMIS we are using our platform for rationally designing potentially best-in-class treatments for next-generation therapeutics to treat Alzheimer’s and other neurologic diseases. #AlzheimersDisease #neurology #FDA

CSO Dr. Neil Cashman presented a talk entitled “Abeta oligomer targeting in Alzheimer Disease” to an audience of industry and academic scientists at the Neuro4D conference in Mainz, Germany May 15-16. Dr. Cashman’s talk highlighted the first-in-class specificity of ProMIS therapeutic antibody PMN310 for Abeta oligomers, while sparing Abeta monomers and plaque fibrils. Other clinical stage antibodies can react with monomers, diluting their activity against oligomers, and plaque fibrils, associated with the serious adverse effect of neurovascular edema called ARIA-E.

Click through to view the video on VJNeurology: https://bit.ly/3I4KBdI Johanne Kaplan, PhD, ProMIS™ Neurosciences, Inc., Cambridge, MA, introduces the TDP-43 program for amyotrophic lateral sclerosis (ALS) at ProMIS™ Neurosciences, Inc.